Table 2 Ferroptosis and cancer therapy

Chemotherapy

Sorafenib

siRNA

Inhibit the MT-1G and the system xc-

HCC, RCC, NSCLC, PDAC

[34, 67, 134, 135]

Artemisinin

Iron

Increase the level of intracellular free iron

PDAC, AML, HNSCC

[122,123,124,125]

Cyst(e)inase

FINs

Deplete extracellular cystine

PDAC, Prostate cancer,

Chronic lymphocytic leukemia

[109, 116]

Statins

-

Reduce selenoproteins (such as GPX4) and CoQ10 biosynthesis

Breast Cancer

[138]

Radiotherapy

RT

FINs

Up-regulates ACSL4,

inhibit SLC7A11 or GPX4

Neuroblastoma, NSCLC, Fibrosarcoma, Melanoma, Breast Cancer,

Cervical cancer

[140,141,142,143,144,145]

Immunotherapy

PD-L1 inhibitors

FINs

Releas IFNγ to reduce the uptake of cystine

Fibrosarcoma

[11]

TGF-β inhibitors and PD-1 antibodies

FINs

Generate an immunogenic microenvironment and produce H₂O2, promoting the Fenton reaction

Melanoma

[146]

Nanomedicine

Metal–Organic Frameworks (MOF)

–

Release iron

Mononuclear macrophage leukemia

[148]

FePt-NP2

Iron nanoparticles and cisplatin

Increase the sensitivity of cancer cells to cisplatin

Ovarian cancer

[117]

SRF@FeIIITA (SFT)

Fe³⁺ and TA, nanocrystals of SRF,

Inhibit GPX4 and generate ROS

Fibrosarcoma

[71]

Nano-delivery vehicle

WithaferinA, IKE

Improve solubility and biocompatibility, and increase accumulation

Neuroblastoma, DLBCL

[84, 99]

AMSNs

Target cancer by ASS and release Mn ion to consume GSH

HCC

[149]

MON-p53

Providie unstable iron, and deliver p53 to cells

Fibrosarcoma

[150]

Ultra-small poly(ethylene glycol) coated silica nanoparticles

Transport of extracellular iron into the cell

NeuroblastomaHCC

[151]

PDT

FINs

Produce ROS and consume O₂

OTSCC, Breast Cancer, HCC

[152,153,154,155,156,157]

PTT

SRF@MPDA-SPIO, FPMF@CpGODN

Release iron and SRF,

produce ROS and consume O₂

CRC, Breast Cancer

[121, 158, 159]